A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis.

Ragweed pollen is the most frequent cause of allergic rhinitis in the late summer-fall in North America. The objectives of this multicenter, randomized, single-blind study are to assess the efficacy and safety of triamcinolone acetonide aqueous (TAA AQ) and beclomethasone dipropionate aqueous (BDP) in the treatment of adult patients with seasonal ragweed-induced allergic rhinitis. Patient's self-assessment of comfort with medication and health-related quality of life were also assessed.

Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial.

Background: Allergic rhinitis is a common disease altering quality of life. Its treatment is well established and guidelines have been proposed. However, their efficacy has never been tested.

Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.

Background: Although they have comparable safety and efficacy profiles, different intranasal corticosteroids possess different sensory/chemical properties that can be easily differentiated by patients, and which may influence their preference and compliance.

Objective: We sought to compare patient assessments of sensory attributes of three intranasal corticosteroid sprays: triamcinolone acetonide aqueous (TAA), fluticasone propionate (FP), and mometasone furoate (MF).

Methods: In a multicenter, randomized, double-blind, crossover study, 95 patients with allergic rhinitis rated 14 sensory items (100-point scales), product preference, and likelihood of compliance with treatment.